14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
2 citations
,
November 2019 in “Skin appendage disorders” Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Mononuclear cells may protect against certain chemotherapy-induced hair loss.
23 citations
,
August 1983 in “PubMed” Clq deficiency is linked to systemic lupus erythematosus symptoms.
85 citations
,
January 1996 in “International Journal of Cancer” The study demonstrated that the immunomodulator AS101 reduced the severity of chemotherapy-induced alopecia in both human and animal models. In a phase-II clinical trial involving 58 non-small-cell-lung-cancer patients, those treated with AS101 combined with chemotherapy experienced significantly less alopecia compared to those receiving chemotherapy alone. In rats, AS101 provided protection against alopecia when combined with Ara-C, with the effect mediated by macrophage-derived factors, particularly IL-1. The protective role of AS101 was also linked to PGE2 secretion, as indomethacin injections reduced its effectiveness. These findings led to further phase-II clinical trials to explore AS101's protective potential in cancer patients with various malignancies.